Drw Securities, LLC Abb Vie Inc. Transaction History

Drw Securities, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$154.79 - $180.76 $911,867 - $1.06 Million	-5,891 Reduced 53.48%	5,125 $879,000
Q1 2024 May 14, 2024	BUY	$159.82 - $182.1 $1.49 Million - $1.7 Million	9,346 Added 559.64%	11,016 $2.01 Million
Q4 2023 Feb 16, 2024	SELL	$137.6 - $154.97 $281,254 - $316,758	-2,044 Reduced 55.04%	1,670 $258,000
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $222,160 - $257,182	-1,663 Reduced 30.93%	3,714 $554,000
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $242,625 - $301,931	-1,831 Reduced 25.4%	5,377 $724,000
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $1.04 Million - $1.2 Million	7,208 New	7,208 $1.15 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $792,140 - $1.01 Million	-5,756 Reduced 70.08%	2,458 $376,000
Q1 2022 May 12, 2022	BUY	$131.98 - $163.75 $475,523 - $589,991	3,603 Added 78.14%	8,214 $1.33 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $295,325 - $373,671	2,749 Added 147.64%	4,611 $624,000
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $477,204 - $541,698	-4,485 Reduced 70.66%	1,862 $200,000
Q2 2021 Aug 12, 2021	BUY	$105.21 - $117.21 $667,767 - $743,931	6,347 New	6,347 $715,000
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $5.01 Million - $6.71 Million	-68,302 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$64.5 - $97.79 $4.41 Million - $6.68 Million	68,302 New	68,302 $5.2 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $2.06 Million - $2.75 Million	-22,344 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $2 Million - $2.19 Million	22,344	22,344 $2.16 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Drw Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Drw Securities, LLC with notifications on news.